Two Houston companies have combined their businesses. Photo by Sergio Trevino

A Houston-based cannabis company has formalized its ongoing relationship with one of the city’s most popular breweries. Bayou City Hemp Company announced that it has purchased 8th Wonder Brewery, Distillery, and Cannabis.

The acquisition deepens a relationship that dates back to 2021, when 8th Wonder and Bayou City Hemp partnered to create Wonder Water, a non-alcoholic beverage available with either CBD or Delta-8 that became the top-selling to-go product at 8th Wonder.

Going forward, the combined company aims to capture a healthy share of the Texas market for adult beverages by offering a full lineup of beer, spirits, and cannabis-infused drinks.

“Our commitment to provide quality products and trusted brands to consumers is strengthened with 8th Wonder, who has been a Texas staple in craft beer and spirits for over a decade,” Bayou City CEO Benjamin Meggs said in a statement. “We look forward to growing market share and distribution to the entire portfolio of products through expanded resources and combined expertise. This is not merely an acquisition; it is a bold declaration of our intent to lead and innovate in the heart of Texas.”

The combined company aims to utilize 8th Wonder’s existing distribution channels to get its products on to as many store shelves as possible, including stores such as H-E-B, Walmart, Kroger, Total Wine, and Spec’s. A capital infusion from Bayou City Hemp will focus on marketing and promotion, helping the company to increase excitement for and awareness of the brand.

“Significant capital will be infused to build out the necessary infrastructure,” Meggs said in response to CultureMap’s request for comment about the combined company’s plans. “This infrastructure will enhance our operational capabilities positioning Bayou City to enter new emerging beverage categories such as Cannabis, NA Beer, and RTD Spirits [ready-to-drink] among others.”

While all those changes will mostly happen behind the scenes, customers will notice upgrades to the current 8th Wonder brewery, taproom, distillery, and beer garden to match the brand’s new look.

Founded in 2011, 8th Wonder Brewery evolved out of the Eatsie Boys food truck. Branded with a nostalgic affection for Houston, it developed a following for beers such as Dome Faux’m (cream ale), Rocket Fuel (Vietnamese coffee porter), and Haterade (gose). Over time, it expanded into spirits with a distillery and cannabis with a dispensary.

Bayou City Hemp Company opened in 2019. It produces edibles, vapes, additives, and seltzers that aim to meet the growing consumer demand for cannabis-based products.

Going forward, Meggs will remain in his role as CEO where he’ll be joined by Bayou City Hemp’s existing chief business officer, Jeromy Sherman, CFO Karen Trotter, chief revenue officer Joel Canada, and chief innovation officer Stephen Horton. 8th Wonder co-founder Ryan Soroka will serve as chief brand and marketing officer, while 8th Wonder co-founder and brewmaster Aaron Corsi will become COO.

“From day one at 8th Wonder, our goal was to build a hundred-year company,” Soroka added. “This transaction will provide the leadership and resources needed to achieve that dream. We look forward to a refreshed and revitalized 8th Wonder as we move forward with Bayou City Hemp into the exciting future of the beverage and cannabis industries.”

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”